VEGF gene therapy meets modality’s high safety bar

A demonstration of efficacy with no inflammatory safety signals from 4DMT's anti-VEGF gene therapy has seemingly won over investors to the viability of a one-time injection of a vectorized biologic, over chronic injections into the eye.

4d Molecular Therapeutics Inc. (NASDAQ:FDMT) reported that in the Phase II SPECTRA study to treat diabetic macular edema, the high dose of 4D-150, which is projected to be the Phase III dose, led to a sustained gain of best corrected visual acuity of +9.7 letters and reduced the need for supplemental aflibercept injections. ...